In the CheckMate 577 clinical trial, the rates of patients free of recurrence during follow-up show a clear trend toward a decreased risk of recurrence over time in both treatment arms and indicate the likely occurrence of a plateau in recurrence-free survival in the medium term.
← all excerpts
A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France.
1
—
—